Radiation, chemo, and immunotherapy before surgery for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple-negative breast cancer (confirmed by biopsy).
- Your tumor must be larger than 2 cm, or have spread to lymph nodes under the arm, or be too large for breast-conserving surgery.
- You must be 18 years or older and in generally good health (ECOG performance status 0 or 1).
- You must not have had chemotherapy, targeted therapy, or radiation for any cancer in the past 12 months.
- You must not have serious heart problems, poorly controlled high blood pressure, or a chronic lung condition like interstitial lung disease.
- You must not have an active autoimmune disease or be taking high-dose steroids or other immunosuppressants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
This trial tests a new drug combination given before surgery for triple-negative breast cancer. The drugs include an immunotherapy medication (AK112) and standard chemotherapy, and the goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a new way to treat triple-negative breast cancer before surgery by combining radiation therapy with an immunotherapy drug and chemotherapy. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.